| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.8 |
| mRNA | temsirolimus | FIMM | pan-cancer | AAC | -0.036 | 0.8 |
| mRNA | COL-3 | CTRPv2 | pan-cancer | AAC | -0.0077 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.8 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.007 | 0.8 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.8 |
| mRNA | Panobinostat | CCLE | pan-cancer | AAC | -0.0081 | 0.8 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | -0.007 | 0.8 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.8 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.8 |